Literature DB >> 12799048

Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1.

Chuanjing Wu1, Rongjiang Yang, Ji Zhou, Shing Bao, Li Zou, Pinggan Zhang, Yongrong Mao, Jianping Wu, Qimin He.   

Abstract

Egg yolk is a good source of highly specific antibodies against mammalian antigens because of the phylogenetic distance between birds and mammals. Chicken egg yolk immunoglobulins (IgY) were generated to a synthetic 31-amino acid peptide from the C-terminal of human HeLa thymidine kinase 1 (TK1) enzyme. The anti-TK1 IgY antibody was purified using affinity chromatography against the 31-amino acid peptide. The purified antibody inhibited the catalytic activity of the TK1 enzyme in the CEM TK1(+) cells and recognized the 25-kDa subunit and tetrameric form of TK1, which has a pI value of 8.3. No immunoreaction was observed in CEM TK1(-) cells. Western blot of the serum TK1 (S-TK1) also showed that only a single band was found in the serum of patients with malignancies. No band was seen in healthy serum. Furthermore, dot blots and enhanced chemiluminescence (ECL) detection of S-TK1 performed on sera of preoperative patients with gastric cancer (GC) (n=31) and healthy controls (n=62) showed that the levels of S-TK1 in the sera of cancer patients were significantly different (P<0.01). Using ECL dot blots, 0.1 pg of TK1 in 3 microl sera could be detected. Immunohistostaining of tissues in the 11 advanced-stage cancer patients (four breast carcinomas, three hepatocarcinomas and four thyroid carcinomas) indicated that a strong staining of TK1 enzyme was found in the cytoplasm of malignant cells. No staining or weak staining was seen in normal tissues. We suggest that screening for TK1 using anti-TK1 IgY may be potentially useful for serological and immunohistochemical detection of TK1 as an early prognosis and for monitoring patients undergoing treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799048     DOI: 10.1016/s0022-1759(03)00062-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  21 in total

1.  Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.

Authors:  Yan Chen; Mingang Ying; YanSong Chen; Minhua Hu; Yingying Lin; Dedong Chen; Xiaoli Li; Ming Zhang; Xia Yun; Ji Zhou; Ellen He; Sven Skog
Journal:  Int J Clin Oncol       Date:  2010-04-01       Impact factor: 3.402

2.  Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.

Authors:  Zhu-Lin Pan; Xing-Ying Ji; Yan-Min Shi; Ji Zhou; Ellen He; Sven Skog
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-07       Impact factor: 4.553

3.  Chicken egg yolk antibodies specific for the gamma chain of human hemoglobin for diagnosis of thalassemia.

Authors:  Pornrutsami Jintaridth; Chantragan Srisomsap; Kanjana Vichittumaros; Ruchaneekorn W Kalpravidh; Pranee Winichagoon; Suthat Fucharoen; M R Jisnuson Svasti; Watchara Kasinrerk
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

4.  XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.

Authors:  Stefan Aufderklamm; Jörg Hennenlotter; Tilman Todenhoefer; Georgios Gakis; David Schilling; Ulrich Vogel; Ursula Kuehs; Johannes Dlugosch; Judith Knapp; Axel Merseburger; Valentina Gerber; Anna Ordelheide; Joachim Hevler; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2011-10-04       Impact factor: 4.226

5.  Serum thymidine kinase 1 is a reliable maker for the assessment of the risk of developing malignancy: A case report.

Authors:  Zhiheng Chen; Hong Guan; Hong Yuan; Xia Cao; Yingxin Liu; J I Zhou; Ellen He; Sven Skog
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

6.  XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma.

Authors:  Georgios Gakis; Joerg Hennenlotter; Marcus Scharpf; Joachim Hevler; David Schilling; Ursula Kuehs; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2010-11-27       Impact factor: 4.226

7.  The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells.

Authors:  Pengcheng Luo; Naining Wang; Ellen He; Staffan Eriksson; Ji Zhou; Guozhu Hu; Jie Zhang; Sven Skog
Journal:  Pathol Oncol Res       Date:  2009-12-03       Impact factor: 3.201

8.  Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer.

Authors:  Zhi-Heng Huang; Xing-Song Tian; Rong Li; Xian-Ming Wang; Wen Wen; Hong Guan; Ya-Jie Yang
Journal:  Exp Ther Med       Date:  2011-11-28       Impact factor: 2.447

9.  Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma.

Authors:  Bao-Jin Wu; Wen-Peng Li; Cheng Qian; Wei Ding; Zhong-Wen Zhou; Hua Jiang
Journal:  Tumour Biol       Date:  2012-11-21

10.  Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer.

Authors:  Lena Carlsson; Anders Larsson; Henrik Lindman
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.